文献速递免疫规划慢病防控与筛查

瑞典斯德哥尔摩县带状疱疹疫苗Zostavax®有效性研究

Effectiveness of the herpes zoster vaccine Zostavax® in Stockholm County, Sweden.
PubMed 文献 · Vaccine · 2019-06-21

结果显示Zostavax总体有效性为34%(HR=0.66,95%CI:0.55-0.78),61-75岁年龄组及接种后180-719天显示显著保护效果。

要点

  • Zostavax总体有效性34%(HR=0.66,95%CI:0.55-0.78)。
  • 仅61-75岁年龄组显示带状疱疹风险降低(HR=0.57,95%CI:0.44-0.73)。
  • 接种后180-719天各时间段疫苗有效性均显著。

核心结论

  • Zostavax在瑞典人群中总体有效性为34%,与既往研究一致,但仍需纵向疗效研究。

主要发现

  • Zostavax总体有效性34%(HR=0.66,95%CI:0.55-0.78)。
  • 61-75岁年龄组带状疱疹风险降低(HR=0.57,95%CI:0.44-0.73),其他年龄组未显示显著降低。
  • 接种后180-359天(HR=0.53,95%CI:0.33-0.88)、360-539天(HR=0.46,95%CI:0.27-0.80)和540-719天(HR=0.56,95%CI:0.35-0.90)疫苗有效性显著。

临床怎么用

  • 在50岁以上人群中接种Zostavax可降低带状疱疹风险,尤其对61-75岁人群保护效果显著。

局限性

  • 研究为回顾性设计,可能受混杂因素影响;需进一步纵向研究评估长期有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to estimate the effectiveness of the herpes zoster vaccine Zostavax in a cohort of vaccinated individuals in Sweden. METHODS: The study is a retrospective population-based matched cohort study conducted with data from health care registers in Stockholm Country. Primary endpoints were new diagnosis of HZ after administration of Zostavax. Individuals above the age of 50 years and living in Stockholm County in 2013 were included into the study. Ten non-vaccinated individuals per vaccinated were included and randomized into the cohort. The non-vaccinated were matched on age at index date and gender. RESULTS: Zostavax had an overall effectiveness (VE) of 34% (HR = 0.66, 95% CI: 0.55-0.78). When stratifying by age, 61-75 years was the only age group that showed a reduced risk of HZ (HR = 0.57; CI 0.44-0.73) compared to those that were non-vaccinated. As compared to the unvaccinated group, the VE was significant at days 180-359 (HR = 0.53; 95% CI 0.33-0.88), 360-539 (HR = 0.46; 95% CI 0.27-0.80) and at days 540-719 (HR = 0.56; 95% CI 0.35-0.90) after vaccination. CONCLUSION: This is the first population-based study in Sweden studying the effectiveness of HZ vaccination. Our findings are well in-line with previous studies, however studies addressing the longitudinal efficacy and effectiveness of Zostavax are still required.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Blom K, Yin L, Arnheim-Dahlström L, et al. Effectiveness of the herpes zoster vaccine Zostavax® in Stockholm County, Sweden. Vaccine. 2019. PMID: 31230884. doi:10.1016/j.vaccine.2019.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。